

## Successful A\$75 million placement and launch of up to A\$5 million SPP

Funds will support accelerated commercialisation and expansion of Salix® software in the U.S. market.

**PERTH, Australia, 9 September 2025:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce it has received binding commitments for a A\$75 million two-tranche placement at A\$2.05 per share. The Company also announced the launch of a SPP of up to A\$5 million to eligible shareholders on the record date, being 8 September 2025, at the same price as the Placement.

### Key Points

- **Binding commitments received for A\$75 million two-tranche placement to professional or sophisticated investors (Placement) at A\$2.05 per share (Placement Price).**
- **Placement proceeds to be applied to support accelerated U.S. commercialisation and expansion, customer success and support, market access and reimbursement enablement, product development, research & development and working capital**
- **Launch of up to A\$5 million share purchase plan (SPP) at the same price as the Placement.**

The capital raising will enable an acceleration in the U.S. commercial entry and expansion of the Company's Salix® platform following recent U.S. Food and Drug Administration (FDA) clearance of Salix® Coronary Plaque (SCP) module. Funds raised will be applied to U.S. commercial expansion, customer success and support, market access enablement, product development, research & development and working capital including the flagship plaque study (SAPPHIRE).

Petra Capital acted as Sole Lead Manager and Sole Bookrunner to the Placement.

#### **John Konstantopoulos, Co-Founder and CEO of Artrya commented:**

*"We are delighted with the strong support for the Placement and welcome a number of highly credentialled local and offshore institutional investors to the register. Existing eligible shareholders, on the record date, will also have the opportunity to participate in the capital raising through the SPP at the same price as the Placement.*

*On behalf of the Board, I would like to thank the Artrya team for their continued dedication, our existing shareholders for their ongoing support, and welcome our new shareholders to the register. We sincerely appreciate their confidence in Artrya and look forward to their support as we advance through this exciting next phase.*

*The success of the capital raising affirms both market recognition, and our belief, in the importance of the Salix® software in addressing the large and growing global health challenge of coronary artery disease.*

*Funds raised will be used to accelerate the commercial roll-out of Salix® software in the U.S., expand adoption across major U.S. hospital groups, and advance the SAPPHIRE study to generate clinical evidence for assessing and treating patients at risk of coronary artery disease."*

### Placement Details

The A\$75 million two-tranche placement of 36,585,366 shares. Approximately A\$60 million (Tranche One) will be raised under the Company's remaining placement capacity (17,645,867 under ASX Listing Rule 7.1 and 11,763,911 shares under ASX Listing Rule 7.1A). A further approximately A\$15 million (Tranche Two), 7,175,588 shares, will be completed subject to shareholder approval at a General Meeting of the Company to be held on or around 24 October 2025.

The Placement Price of A\$2.05 per share represents a 6.0% discount to the last closing price of A\$2.18 and a 4.7% discount to the 10-trading day volume weighted average trading price to 4 September 2025.

## SPP Details

The Company has also launched a A\$5 million share purchase plan, to eligible shareholders on the record date, being 8 September 2025. Eligible shareholders will be entitled to apply for up to A\$30,000 at the same price as the Placement.

The SPP is expected to open on 15 September 2025 and close on 3 October 2025, with new shares under the SPP expected to be issued on or before 10 October 2025.

The Company reserves the right to accept oversubscriptions under the SPP, at the sole discretion of the Board, or place any SPP shortfall.

## Timetable

The following timetable is indicative only and may be subject to change at the sole discretion of the Company, in consultation with the Lead Manager, and in compliance with the ASX Listing Rules and Corporations Act.

<b>SPP Record Date</b>	8 September 2025
<b>Placement &amp; SPP Announcement</b>	9 September 2025
<b>Placement Tranche One Settlement Date</b>	12 September 2025
<b>Placement Tranche One Allotment Date</b>	15 September 2025
<b>SPP Opening Date</b>	15 September 2025
<b>SPP Closing Date</b>	3 October 2025
<b>SPP Results Announced &amp; shares issued</b>	On or before 10 October 2025
<b>General Meeting</b>	On or around 24 October 2025
<b>Placement Tranche Two Settlement Date</b>	30 October 2025
<b>Placement Tranche Two Allotment Date</b>	31 October 2025

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

## About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](https://www.linkedin.com/company/artrya)

## Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

## Not an offer of securities

This Announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This Announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

## For more information:

### Corporate Enquiries

**John Konstantopoulos**  
Co-Founder and Chief Executive Officer  
Tel: +61 8 6478 7816  
Email: [contact@artrya.com](mailto:contact@artrya.com)

### Investor & Media Enquiries

**David Allen or John Granger**  
Hawkesbury Partners  
Tel: +61 499 100 038 or +61 410 577 155  
Email: [investors@artrya.com](mailto:investors@artrya.com)